Host kinase CSNK2 is a target for inhibition of pathogenic β-coronaviruses including SARS-CoV-2
Abstract
Inhibition of the protein kinase CSNK2 with any of 30 specific and selective inhibitors representing different chemotypes, blocked replication of pathogenic human and murine β-coronaviruses. The potency of in-cell CSNK2A target engagement across the set of inhibitors correlated with antiviral activity and genetic knockdown confirmed the essential role of the CSNK2 holoenzyme in β-coronavirus replication. Spike protein uptake was blocked by CSNK2A inhibition, indicating that antiviral activity was due in part to a suppression of viral entry. CSNK2A inhibition may be a viable target for development of new broad spectrum anti-β-coronavirus drugs.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 04, 2022
- Source ID
- 10.1101/2022.01.03.474779
Entities
People
- Alison D Axtman
- Armin Bayati
- Boyd L Yount
- Carrow Wells
- Edcon Chang
- Emily A Madden
- Erik M. Lenarcic
- Jason W. Brown
- Jeffery L. Smith
- Mark T Heise
- Nathaniel J. Moorman
- Peter S McPherson
- Ralph S. Baric
- Rebekah J. Dickmander
- Sharon Taft-Benz
- Timothy M Willson
- Xuan Yang